Table 4.
Baseline clinical characteristics of the three groups after propensity score matching.
| Parameters | Total (n=81) | IM (n=27) | IM+HR (n=27) | IM+RFA/ TACE (n=27) | P | SMD |
|---|---|---|---|---|---|---|
| Age (years) | 0.934 | 0.058 | ||||
| ≤60 | 62 (76.54) | 20 (74.07) | 21 (77.78) | 21 (77.78) | ||
| >60 | 19 (23.46) | 7 (25.93) | 6 (22.22) | 6 (22.22) | ||
| Sex | 0.354 | 0.262 | ||||
| Female | 28 (34.57) | 7 (25.93) | 9 (33.33) | 12 (44.44) | ||
| Male | 53 (65.43) | 20 (74.07) | 18 (66.67) | 15 (55.56) | ||
| Primary sites | 0.663 | 0.050 | ||||
| Stomach | 37 (45.68) | 13 (48.15) | 12 (44.44) | 12 (44.44) | ||
| Small intestine | 40 (49.38) | 13 (48.15) | 14 (51.85) | 13 (48.15) | ||
| Colorectum | 1 (1.23) | 0 (0.00) | 1 (3.70) | 0 (0.00) | ||
| Others | 3 (3.70) | 1 (3.70) | 0 (0.00) | 2 (7.41) | ||
| Metastatic phase | 1.000 | <0.001 | ||||
| Synchronous | 45 (55.56) | 15 (55.56) | 15 (55.56) | 15 (55.56) | ||
| Metachronous | 36 (44.44) | 12 (44.44) | 12 (44.44) | 12 (44.44) | ||
| Number of metastases | 1.000 | <0.001 | ||||
| ≤3 | 42 (51.85) | 14 (51.85) | 14 (51.85) | 14 (51.85) | ||
| >3 | 39 (48.15) | 13 (48.15) | 13 (48.15) | 13 (48.15) | ||
| Largest diameter of metastases (cm) | 0.951 | 0.050 | ||||
| ≤3 | 44 (54.32) | 14 (51.85) | 15 (55.56) | 15 (55.56) | ||
| >3 | 37 (45.68) | 13 (48.15) | 12 (44.44) | 12 (44.44) | ||
| Extrahepatic metastases | 0.479 | 0.186 | ||||
| No | 66 (81.48) | 23 (85.19) | 23 (85.19) | 20 (74.07) | ||
| Yes | 15 (18.52) | 4 (14.81) | 4 (14.81) | 7 (25.93) | ||
| Gene mutation | 0.351 | 0.100 | ||||
| KIT_exon 9 | 12 (14.81) | 4 (14.81) | 3 (11.11) | 5 (18.52) | ||
| KIT_exon 11 | 33 (40.74) | 11 (40.74) | 11 (40.74) | 11 (40.74) | ||
| Wild type | 3 (3.70) | 0 (0.00) | 3 (11.11) | 0 (0.00) | ||
| Others | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||
| Unknown | 33 (40.74) | 12 (44.44) | 10 (37.04) | 11 (40.74) | ||
| IM response before surgical treatmenta | 0.511 | 0.083 | ||||
| PR | 5 (9.26) | — | 4 (14.81) | 1 (3.70) | ||
| SD | 20 (37.04) | — | 9 (33.33) | 11 (40.74) | ||
| Extensive progression | 1 (1.85) | — | 1 (3.70) | 0 (0.00) | ||
| Limited progression | 14 (27.45) | — | 6 (22.22) | 8 (29.63) | ||
| NA | 14 (27.45) | — | 7 (25.93) | 7 (25.93) | ||
| Status after surgical treatmenta | 0.056 | 0.538 | ||||
| NED | 29 (53.70) | — | 18 (66.67) | 11 (40.74) | ||
| non-NED | 25 (46.30) | — | 9 (33.33) | 16 (59.26) | ||
| Combined with other local therapy | — | — | ||||
| No | — | — | 19 (70.37) | — | ||
| RFA | — | — | 5 (18.52) | — | ||
| TACE | — | — | 2 (7.41) | — | ||
| RFA+TACE | — | — | 1 (3.70) | — |
Values are presented as n (%).
P-values were calculated using a two-sided χ2 test.
a
Suitable for surgical treatment group (n=112).
HR, hepatic resection; IM, imatinib; NA, not applicable; NED, no evidence of disease; PR, partial response; RFA, radiofrequency ablation; SD, stable disease; SMD, standard mean difference; TACE, transarterial chemoembolization.